Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3719-3728

  Frankel, A ^a   Man, S ^a   Elliott, P ^a   Adams, J ^a   Kerbel, R S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CASPASE INHIBITOR; CYTOTOXIC AGENT; DIPEPTIDE DERIVATIVE; N BENZYLOXYCARBONYLVALYLALANYLASPARTYLFLUOROMETHYLKETONE; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BORONIC ACIDS; CARCINOMA; CASPASES; CELL ADHESION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0033817518     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Treatment of malignancies, past and present
2. Modes of resistance to antitumor agents
3. Cell and environment interactions in tumor microregions: The multicell spheroid model
4. Drug and radiation resistance in spheroids: Cell contact and kinetics
5. Cell adhesion and drug resistance in cancer
6. Cellular and molecular basis of chemotherapy
7. Implication of cell kinetic changes during the progression of human prostatic carcinoma
8. Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors
9. Effects of nIFN β and rIFN γ on growth and morphology of two human melanoma cell lines: Comparison between two- and three-dimensional culture
10. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis
11. Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin
12. How proteolysis drives the cell cycle
13. New insights into proteasome function: From archaebacteria to drug development
14. Structure and functions of the 20S and 26S proteasomes
15. In vivo ubiquitination and proteasome-mediated degradation of p53
16. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis
17. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
18. The ubiquitin-proteasome pathway: On protein death and cell life
19. An essential role for NF-κB in preventing TNF-α-induced cell death
20. Suppression of TNF-α-induced apoptosis by NF-κB
21. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
22. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
23. Proteasome inhibitors: A novel class of potent and effective antitumor agents
24. Acquired multicellular-mediated resistance to alkylating agents in cancer
25. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIPI)
26. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture
27. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells
28. 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids
29. Prostate carcinoma response to cytotoxic therapy: In vivo resistance
30. The genetics of proteasomes and antigen processing
31. The ubiquitin-proteasome pathway is required for processing the NF-κ B1 precursor protein and the activation of NF-κ
32. Proteasomes: Destruction as a programme
33. The ubiquitin-mediated proteolytic pathway as a therapeutic area
34. Proteasome inhibitors: Valuable new tools for cell biologists
35. Eponemycin exerts its antitumor effect through the inhibition of proteasome function
36. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis
37. Role of proteasomes in T cell activation and proliferation
38. p53-Dependent induction of apoptosis by proteasome inhibitors
39. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells
40. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line
41. Ubiquitin-mediated degradation of the proapoptotic active form of Bid: A functional consequence on apoptosis induction
42. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
43. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: Possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells
44. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system
45. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
46. The proteasome inhibitor PS-341 in cancer therapy
47. The ubiquitin-proteasome pathway in cancer
48. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
49. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis